Antiestrogen resistance in estrogen receptor positive (ER + ) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identified 10 regulators of IGF1R-mediated antiestrogen with clinical significance. These include the tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes, particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER + metastatic breast cancer patients is correlated with unfavorable outcome after first-line tamoxifen monotherapy. Phosphoproteomics has defined PAK2 and the PAK-interacting exchange factors PIXα/β as downstream targets of IGF1R signaling, which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIXα/β modulate IGF1R signaling-driven cell scattering. Targeting PIXα/β entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.
Introduction
More than 70% of breast cancers are estrogen receptor positive (ER + ) and dependent on estrogen for growth and progression [1] . Antiestrogen therapy by tamoxifen or fulvestrant has been the front-line treatment for ER + breast cancers [2, 3] . Despite the effectiveness at first, around 50% of the treated breast cancers will become antiestrogenresistant [4, 5] . Antiestrogen resistance is attributed to loss of ER expression or function in breast cancers where ER does not actually play a central role [6, 7] . Additionally, resistant breast cancers often show upregulated signaling of receptor tyrosine kinases, including epidermal growth factor receptor [8, 9] , HER2 [10, 11] and insulin-like growth factor 1 receptor (IGF1R) [12] [13] [14] . High IGF1R expression is associated with migration and invasion of breast cancer and metastasis-free survival of ER + breast cancer patients [15] [16] [17] [18] [19] . IGF1R activation by insulin-like growth factor 1 (IGF-1) promotes cell death resistance of ER + breast cancer cells [17] . poor outcome [20] . Several high-throughput screening studies have mapped IGF1R as a candidate target to resensitize tamoxifen resistant breast cancer cells [12, 21, 22] . We and others have demonstrated that IGF1R signaling can confer resistance to antiestrogen treatment regardless of ER activity [12, 14] . IGF1R is coupled to multiple downstream pathways and, besides PI3K/AKT and MAPK/ERK signaling [14] , it is unresolved which of these contribute to antiestrogen resistance.
Here we performed a small interfering RNA (siRNA) screen targeting all kinases and phosphatases to unravel signaling cascades underlying IGF1R-mediated antiestrogen resistance. For identified candidate targets to combat resistance, association was determined with clinical outcome of metastatic ER + breast cancers treated with first-line of tamoxifen monotherapy. Our results reveal PAK2, as well as the PAK-interacting exchange factors PIXα/β, as a critical determinant in IGF1R-mediated antiestrogen resistance with significant clinicopathological correlation to tamoxifen resistance development.
Results
Kinome siRNA screen of IGF1R-mediated tamoxifen resistance [14] . Using this cell model, we performed a human kinase and phosphatase siRNA primary screen under the tamoxifen resistance condition, as schemed (Supplementary Fig. 2A ). Replica screens displayed high reproducibility (Fig. 1a, b) . Z-score ranking revealed 66 kinases and 8 phosphatases whose knockdown increased cell proliferation, and 79 kinases and 21 phosphatases whose targeting inhibited cell proliferation (Fig. 1a, b and Supplementary Table 1 ). We classified the former genes as tamoxifen resistance suppressors, meaning that their expression or signaling may suppress tamoxifen resistance, and the latter as tamoxifen resistance inducers, meaning that their expression or signaling induces tamoxifen resistance. Next, we validated all tamoxifen resistance inducers and a few top ranked or clinically relevant tamoxifen resistance suppressors (as mentioned below), for their on-target silencing by SMARTpool siRNA and its 4 deconvoluted siRNAs and for their functional relevance to tamoxifen resistance status, compared to E2 and IGF-1 stimulation ( Supplementary Fig. 2B ). All validated 114 hits displayed positive effect under the resistance condition (Supplementary Fig. 3A) . The majority of hits were ontarget ( Fig. 1c and Supplementary Fig. 4 ). Fifty-one hits were common to all conditions, while others were specific to one or two conditions ( Fig. 1d and Supplementary Fig.  4 ). Particularly, several positive hits showed no effect or an opposite effect under IGF-1 or E2 condition, implying their distinct roles in IGF1R-mediated tamoxifen resistance ( Supplementary Fig. 3B and C) . These included Abl1, CKM, MAP4K3, NTRK2, PAK2, RPS6KC1, SAST, SSTK, TAF1, PPP2R5D, and TPTE2.
Clinical relevance of IGF1R-mediated tamoxifen resistance hits
To evaluate the clinical relevance of the screened hits (Supplementary Table 1 ), we analyzed them as continuous variable in our established Agilent 44k oligo-array dataset of 101 ER + metastatic breast cancer (MBC) patients treated with first-line tamoxifen monotherapy [23, 24] . All candidate genes in this dataset could be analyzed for an association with treatment outcome. The results revealed 10 hits with high relevance to poor treatment outcome and progression free survival (PFS) (Fig. 2a) . Significantly, the predicted hazard ratio (HR) is low in patients expressing tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and high in those expressing tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. Furthermore, we evaluated these 10 hits for their prognostic values with the natural course of disease in 221 ER + lymph node negative (LNN) breast cancer patients who did not receive any adjuvant systemic treatment [25] . The results demonstrated that expression levels of BMPR1B, CDK10, EIF2AK1, MAP2K5, CHEK1, and PAK2, were not prognostic in this subset (Fig. 2b) , showing a relationship only with tamoxifen therapy response.
Targeting of tamoxifen resistance inducing hits with clinical relevance restores antiestrogen sensitivity
These 10 hits were on-target under tamoxifen resistance condition, displaying differential effects under IGF-1 or E2 stimulative condition (Fig. 1e) . Next, we established their dose-response relationships to 4OHT (Fig. 3a) and FUL ( Fig. 3b ) in combination with E2 and IGF-1. Compared to siRNA control (siCtrl), silencing of each tamoxifen resistance suppressor enhanced proliferation by IGF-1 and E2, above the siCtrl levels where the resistance remains. In contrast, silencing of the tamoxifen resistance inducer CHEK1, TTK, or TXK significantly reduced IGF-1 and E2 induced proliferation, largely below the siCtrl levels. Of interest, targeting the inducer PAK2 or RPS6KC1 restored the dose-dependent response to 4OHT and FUL, in the presence of IGF-1. Fig. 1 Identification of determinants in IGF1R-mediated tamoxifen resistance by kinome siRNA Screen. a Primary kinase and b phosphatase siRNA screen of MCF7/IGF1R cells under tamoxifen resistance condition where 4OHT (4-hydroxytamoxifen, 1 μM), E2 (17β-estradiol, 1 nM) and IGF-1 (insulin-like growth factor 1, 100 ng/ml) were given. Spearman correlation coefficient R 2 values showed reproducibility of replica screens. The hits for tamoxifen resistance suppressors (Z > mean + 1.5 × SD, P < 0.05; in red) and inducers (Z < mean -1.5 × SD, P < 0.05; in blue) were ranked by Z score plot and numbered in pie charts. siRNAs targeting PTEN, AKT1, and MAPK1, the known regulators in IGF1R-mediuated antiestrogen resistance [14] , were used as functional positive controls ( Supplementary Figs. 1C and   D) . The targeting effects of siPten (increasing proliferation), siAKT1 and siERK2 (decreasing proliferation), and the non-targeting effect of negative control siCtrl were positioned in the Z score plots. c Validation screen of IGF1R-mediated tamoxifen resistance hits. Effects of single siRNAs (siRNA_1, _2, _3 and _4) targeting 114 hits were validated under tamoxifen resistance condition (I) 4OHT + E2 + IGF-1, compared to IGF-1 (II) and E2 (III) stimulation conditions. d The number of hit siRNAs showing on-target effects under condition I, II and III. e Comparison of SMARTpool siRNA and single siRNA_1, _2, _3 and _4 targeting effects on 10 hits, which have clinical relevance (Fig. 2a) , under condition I, II and III in repeated experiment. Values were derived from triplicate samples. Data were expressed as mean ± SD
PAK2 is a target in IGF1R-mediated antiestrogen resistance
Our transcriptomic data revealed the high expression of PAK2 in both parental MCF7 and the established MCF7/ IGF1R cells, compared to any other PAK family members, suggesting a critical role for PAK2 in these cells (Supplementary Fig. 5A-B) . Silencing of PAK2 (siPAK2), but none of the other PAK members that are expressed in the MCF7/ IGF1R cells, PAK1, PAK4 and PAK6 ( Supplementary Fig.  5C -D), inhibited cell proliferation significantly under tamoxifen resistance condition, less so in IGF-1 stimulation or not at all under E2 condition (Fig. 1e) , and restored antiestrogen dose-responses (Fig. 3a, b) . PAK2 predicated the highest HR in tamoxifen-treated patients (Fig. 2a) , leading to poor survival (Fig. 4a) . These results let us first focus on the potential role of PAK2, p21 protein (Cdc42/ Rac)-activated kinase 2, in IGF1R-mediated antiestrogen resistance.
PAK2 on-target silencing re-sensitized MCF7/IGF1R cells (Fig. 4b) . Similar to siCtrl, siPAK2 allowed 4OHT and FUL to antagonize E2 through a dose range, and did not significantly influence IGF-1-stimulated proliferation. Yet, siPAK2 declined the proliferation of the resistant cells under 4OHT or FUL dose-range with E2 plus IGF-1, reaching similar levels under 4OHT/E2 or FUL/E2 antagonizing condition (Fig. 4c) .
Lentiviral shRNA-mediated PAK2 stable knockdown in MCF7/IGF1R cells, shPAK2_1 and shPAK2_2, did not interfere with ER expression (Fig. 4d ), E2 and IGF-1 stimulated proliferation, or the antagonistic effects of 4OHT and FUL on E2 (Supplementary Fig. 6 ). Nonetheless, while IGF-1 provoked resistance in shRNA control (shCtrl) cells, the resistant phenotype was drastically abolished in shPAK2 cells ( Supplementary Fig. 6 ) in 4OHT and FUL concentration-dependent manners (Fig. 4e) . As expected, rescue of PAK2 expression in shPAK2 cells (Fig. 4f) rendered the cells resistant to 4OHT and FUL (Fig. 4g) . These results indicated a pivotal role of PAK2 in controlling IGF1R-mediated antiestrogen resistance.
PAK2 acts downstream of IGF1R signaling independently from PI3K/AKT and MAPK/ERK pathways
Relatively little is reported about activation of PAK signaling in response to IGF-1 stimulation. To decipher IGF-1/ IGF1R assembled signaling networks, we performed a Stable-Isotope Labeling by Amino Acids in Cell Culture (SILAC)-based quantitative phospho-proteomics, as schemed (Fig. 5a ). Quantitative SILAC-based analysis revealed that a number of components in IGF-1 and PAK signaling were highly phosphorylated upon IGF-1 stimulation (Fig. 5b) . Ingenuity Pathway Analysis (IPA) plotted out the crosstalk between the IGF-1 and PAK signaling networks, where the signaling components ATM, MAP2K1, MAP2K2, MAPK1, MAPK3, PIK3C2A, PXN, RAF1, SHC1, and SOS1 were activated (Fig. 5c ).
IGF-1 stimulation induced the phosphorylation of numerous proteins/kinases that regulate cell proliferation, growth and survival programs downstream of IGF1R signaling pathway as mapped by IPA (Fig. 6a.) . These kinases mostly contributed as inducers to IGF1R-mediated tamoxifen resistance, including IGF1R, PI3K catalytic subunits + breast cancer patients who did not receive any adjuvant systemic therapy. This patient cohort has been described by us previously [25] (PIK3CA and PIK3C2G), PDK1, AKT1, p70S6Ks (RPS6KA2, RPS6KB1 and RPS6KC1), Raf1 and MAPK1 ( Supplementary Fig. 5E ). Importantly, SILAC spectra revealed PAK2 phosphorylation at Ser141 (Fig. 6b ). This IGF-1-stimulated PAK2 phosphorylation was rapid and constant ( Fig. 6c and Supplementary Fig. 7A ). IGF1R kinase inhibitor BMS-538924 blocked PAK2 phosphorylation ( Fig. 6d , left panels), confirming PAK2 signaling in IGF-1/IGF1R axis. PAK signaling is linked to Grb2-Raf-ERK and PI3K/ AKT (Fig. 6a ) [26] [27] [28] [29] [30] , the two canonical routes downstream of receptor tyrosine kinase signaling transduction, which are interrelated with IGF-1 and PAK signaling networks (Fig. 5c ). We showed here that PAK2, 
PAK2 suppresses the onset of apoptosis in IGF1R-mediated antiestrogen resistance
PAKs play essential roles in cell-cycle progression and apoptosis prevention [26, 28, 31] . Next, we examined whether PAK2 modulates the cell cycle progression as well as the suppression of apoptosis in response to IGF-1 stimulation. IGF-1 promoted cell-cycle progression (G2/M and S phase) under 4OHT/E2 antagonizing condition, which was suppressed by shPAK2 ( Fig. 6f and Supplementary Fig. 8A ). This suppression coincided with an onset of apoptosis evidently at late time point, which also occurred under 4OHT/E2 ( Fig. 6g and Supplementary Fig.  8B ). We further evaluated this antiapoptotic effect of PAK2 on IGF1R-mediuated resistance to 4OHT in a 3D culture system. While shCtrl cells formed acini under resistance condition, shPAK2 sufficiently abolished the resistant acinar outgrowth ( Fig. 6h and Supplementary Fig. 8C ).
IGF1R-mediated antiestrogen resistance involves PAK2/PIX survival components
PAK2 drives PAK-interacting exchange factor (PIX) activation in modulating cell migration and protrusion, promoting cell growth and survival, and preventing apoptosis [28, [32] [33] [34] . As a Rac effector, PAK2 is also essential for the activation of β-catenin [35] , and the cell-cell adhesion protein β-catenin has been shown to mediate IGF-1/IGF1R action in cell proliferation [36] . We found that overexpression of IGF1R in MCF7 cells led to reduced cell-cell junctions ( Supplementary Fig. 9A ) and conferred a scattering phenotype in IGF-1 stimulation, which was diminished by shPAK2 (Fig. 7a) . SILAC spectra revealed increased phosphorylation levels of PIXα/β (also named Rac/Cdc42 guanine nucleotide exchange factor 6/7, ARH-GEF6/7) (Fig. 5b and Fig. 7b ) as well as β-catenin (Supplementary Fig. 9E ) after IGF-1 stimulation. Membranous staining of the cell-cell adhesion marker E-cadherin showed that silencing of PAK2, PIXα/β or β-catenin inhibited the IGF1-mediated cell scattering phenotype ( Fig. 7c and Supplementary Fig. 9B ) and blocked IGF-1-modulated cell protrusion significantly (Fig. 7d) . Furthermore, targeting PIXα, PIXβ or β-catenin (Fig. 7e) recovered the sensitivity of MCF7/IGF1R cells to antiestrogens 4OHT and FUL (Fig. 7f) , as did siPAK2, in dose-dependent manners ( Supplementary Fig. 9C and D) . The effect of PAK2 was not limited to MCF7/IGF1R cells. Parental MCF7 cells express low level of endogenous IGF1R ( Supplementary  Fig. 1A ) and demonstrate a limited IGF-1-mediated antiestrogen resistance (Supplementary Fig. 1B ). Yet, importantly, also silencing of PAK2, PIXα, PIXβ or β-catenin in parental MCF7 decreased the proliferation under 4OHT or FUL, E2, and IGF-1 resistance conditions ( Supplementary  Fig. 9F ). The involvement of PAK2 (but not other PAK family members), PIXα/β and β-catenin in IGF1R-mediated antiestrogen resistance was also confirmed in T47D/IGF1R, another established ER + breast cancer cell line with ectopic IGF1R overexpression ( Supplementary Fig. 10A-E) . Similar to siPAK2, siPIXα, siPIXβ or β-catenin did not restrict IGF-1-stimulated AKT and ERK phosphorylation in both MCF7/IGF1R (Fig. 7g) and T47D/IGF1R cell lines (Supplementary Fig. 10F ). While PAK1 has been shown to stabilize β-catenin [37] , depletion of PAK2 did not affect β-catenin expression levels in neither MCF7/IGF1R (Fig. 7h ) nor T47D/IGF1R ( Supplementary Fig. 10G ). Of relevance, IGF-1-induced PIXβ phosphorylation was downstream of IGF1R/PAK2 signaling, as siPAK2 inhibited the phosphorylation of PIXβ in IGF-1 stimulation in both resistant cell lines ( Fig. 7h and Supplementary Fig. 10G ). These data indicate PAK2/PIX signaling as a distinct signaling branch downstream of IGF1R activation. Importantly, the PAK2/ PIX-mediated antiestrogen resistance after IGF1R signaling seems to be a general phenomenon.
PAK2 expression is associated with clinicopathological characteristics and progression free survival
Our clinical dataset of 101 MBC patients treated with firstline tamoxifen revealed that PAK2 RNA expression level predicated high HR in disease progression (Fig. 2a) and poor outcome as verified in Kaplan-Meier survival curve (Fig. 4a) . To further assess the clinical relevance of PAK2, we next performed a PAK2 tissue microarray (TMA) staining in 291 patients with primary operable ER + breast cancer who subsequently developed MBC after first-line tamoxifen and for which detailed clinical follow-up was available [38] . TMA results showed that PAK2 protein staining was detected primarily in cytoplasm in 242 of the 291 ER + tumors (83%). The quantity of positive cells was indistinguishable, since almost all tumor cells within the evaluated biopsy cores were PAK2 positive. Staining intensity separated the specimens into 114 with weak staining (47%), 92 with moderate staining (38%), and 36 with strong staining (15%) tumors (Fig. 8a, b) . No significant associations were observed between PAK2 intensity and traditional predictive factors, including age and menopausal status at start of therapy, lymph nodes involved, Table 2 and Table 3 ). There was only a significant relationship with the fraction of HER2/neupositive cells. Strong PAK2 staining was significantly associated with PFS in univariate analysis (HR 1.77, 95% CI 1.13-2.78, P = 0.013) (Figs. 8b, c and Supplementary  Fig. 11A and B) . In multivariate analysis, PAK2 strong staining was related with PFS (HR 1.87, 95% CI 1.18-2.96, P = 0.008) ( Fig. 8b and Supplementary Fig. 11A and B) , when compared to tumors with no PAK2 expression and corrected for the traditional predictive factors. PAK2 staining was not related with overall survival (weak: HR = 1.03, 95% CI 0.71-1.49, P = 0.890; weak/moderate: HR = 0.99, 95% CI 0.67-1.46, P = 0.972; strong: HR = 1.19, 95% CI 0.73-1.93, P = 0.479). These data indicated that high PAK2 expression in MBC patients associates with unfavorable outcome after first-line tamoxifen, strongly suggesting the important clinical correlation of PAK2 to the development of tamoxifen resistance.
Discussion
Our kinome screen of IGF1R-mediated tamoxifen resistance has defined 10 hits with clinical relevance to ER + MBC patients treated with first-line tamoxifen monotherapy [23, 24] . Among tamoxifen resistance suppressors, CDK10 was previously defined as a determinant for tamoxifen resistance [39] , while BMPR1B, CDK5, EIF2AK1, and MAP2K5 are unknown players. The tamoxifen resistance inducer CHK1 has been associated with an impaired tamoxifen response [40] , while the implication of PAK2, RPS6KC1, TTK, and TXK in antiestrogen resistance has not been reported yet. Low expression of the suppressors, or enhanced expression of the inducers, as individual markers, might contribute to developing antiestrogen resistance, thereby leading to poor disease outcome. PAK2, as well as RPS6KC1, modulates the proliferation of resistant cells in an IGF1R-signaling dependent manner, suggesting their potency as novel targets in IGF1R-mediated antiestrogen resistance. PAK2 belongs to p21 protein (Cdc42/Rac)-activated kinase (PAKs) family that consists of six members. PAK expression and activity are often upregulated in human tumors [28, 41] . PAK1 expression is related to tamoxifen response [42, 43] . We report here that PAK2 expression is significantly predictive for unfavorable outcome in two cohorts of 101 and 291 ER + MBC patients with first-line of tamoxifen monotherapy, but not in 221 ER + LNN breast cancer patients without any adjuvant systemic treatment, stressing the clinicopathological correlation of PAK2 to the development of antiestrogen resistance in luminal breast cancer. PAK2 staining intensity was evaluable for 291 ER + primary tumor specimens in our clinical retrospective setting. Recently, a multi-parametric serum marker panel was reported to distinguish breast cancer from healthy control groups. However, the auto-antibodies of this panel, including PAK2, as an individual marker, displayed relative weak discriminatory performance [44] . In our study, almost all tumor cells had some level of PAK2 staining in the majority of tested specimens. Therefore, standard immunoreactive scoring methods combining percentage positive cells with intensity [38] are not appropriate, and also not always applied. For instance, ER and PR in breast cancer are only evaluated for the proportion of positive tumor cells and not for their staining intensities. Rather, we found that analysis of PAK2 staining intensity would be a relevant approach for selection of patients for tamoxifen treatment.
Since our cohort differed in the number of cases with regard to staining intensities and the low magnification images showed that strong PAK2 staining was clearly distinguishable from the other intensities, only intensity was further evaluated. Our univariate and multivariate analyses showed that strong PAK2 staining was related to progression free survival, also independent from traditional factors. Thus our study demonstrated strong PAK2 staining in primary breast tumors of especially patients resistant to tamoxifen of the advanced disease setting. PAKs play pivotal roles in motility, proliferation, mitosis and survival that are required for oncogenesis [28, 45, 46] . Tumor cells with upregulated PAKs tend to become dependent on PAK signaling. It has been uncovered that PAKs interact with downstream β-catenin to promote growth signaling [37, 47] . PAKs have been placed downstream of PI3K/AKT [45] and upstream of MAPK/ERK canonical cascades [46] . And crosstalk occurs within ERK/ AKT and β-catenin signaling networks in cell cycle progression [48, 49] . Our results implicate PAK2/PIX and β-catenin in IGF-1/IGF1R signaling, in a manner that is separate from PI3K/AKT and MAPK/ERK activation. Similar findings have been reported for KRAS-driven proliferation of colon cancer cells [29] . The interaction between PAKs and ERK is complicated. In fibroblast growth factor stimulation, PAK2 is activated downstream of ERK [50] , while PAK activity controls ERK activation in the context of platelet derived growth factor but not epidermal growth factor signaling [51] . Moreover, ERK and AKT activity have been reported to be regulated by distinct PAK family members [52] . Clearly, PAKs regulate and mediate signaling cascades in a highly context-dependent manner in response to different stimuli.
Activation of PAK/PIX components conveys oncogenic signaling to promote cell growth and survival, cell migration and invasion, and prevent apoptosis [28, 32-34, 53, 54] . Our results demonstrate that PAK2 and PIXα/β act downstream of IGF1R signaling to mediate antiestrogen resistance in breast cancer cells. Silencing of PAK2 or PIXα/β attenuates the IGF-1-induced migratory and resistant phenotypes, suggesting that targeting PAK2/PIX survival signaling may provide a novel therapeutic avenue for antiestrogen resistant luminal ER + breast cancers. Future work must be aimed at the identification of pharmacological inhibitors targeting this axis to overcome resistance against antiestrogen therapy in luminal ER + breast cancer.
Materials and methods
High-throughput kinase and phosphatase siRNA screen and data analysis
We performed the high-throughput screen on a Biomek FX (Beckman Coulter) liquid handling system under indicated conditions ( Supplementary Fig. 2 ). The primary screen was carried out by use of SMARTpool siRNAs targeting human genome-wide 779 kinases and 193 phosphatases (Dharmacon, Thermo Fisher). Each primary screen plate included positive and negative siRNA controls. In the validation screen, SMARTpool siRNA and single siRNA_1, _2, _3 and _4 that comprise the SMARTpool mix were used to target each candidate hit. For siRNA transfection, 15,000 cells per well were seeded in 96-well plate overnight, transfected for 2 days in replica cell plates (Replica 1 & 2) with 50 nM siRNA divided from the siRNA transfection plate by use of DharmaFECT 4 transfection reagent (Dharmacon, Thermo Fisher) in 5% charcoal-dextran treated FBS (CDFBS) starving medium, and proliferated for 4 days under indicated condition. The sulforhodamine B (SRB) colorimetric assay was used as read-out for cell proliferation [14] . Primary screen data were analyzed using an unbiased sample-based analysis [55] . Briefly, raw SRB absorbance values of individual siRNA samples in each plate were transformed into Z scores by the formula "Z score = (individual siRNA sample-mean of all siRNA samples)/standard deviation of all siRNA samples". Validation screen data were assessed with a non-targeting control-based Z score analysis by the formula "Z score = (individual siRNA sample-mean of negative controls)/ standard deviation of negative controls". We took Z > | mean ± 1.5 × SD| and P < 0.05 as significant effect.
Antibodies and compounds, 3D culture, Western blot assay, and immunofluorescence staining
Mouse antibody specific for PAK2 (#4825) and rabbit antibody against phospho-PAK1 (Ser144)/PAK2(Ser141) (#2606) were purchased from Cell Signaling, mouse antibody against E-cadherin (6101810) from BD Transduction, mouse antibody against β-PIX (611648) from BD Biosciences, and rabbit antibody against α-PIX (HPA003578) from Sigma. For other antibodies and compounds, and assays used, they were referred to those as previously described [14] .
shRNA knockdown of PAK2
To establish shRNA-mediated PAK2 knockdown, we used two pLKO.1-puro lentiviral plasmids containing validated human PAK2 shRNA Seq1 (TRCN0000002115; Region: 3UTR; sequence: CCGGCTCTAGGAACCAAAGTGA TTTCTCGAGAAATCACTTTGGTTCCTAGAGTTTTT) or Seq2 (TRCN0000194671; region: CDS; sequence: CCGGCGGGATTTCTTAAATCGATGTCTCGAGACA TCGATTTAAGAAATCCC GTTTTTTG) (Sigma-Aldrich; in collaboration with Dr. Rob Hoeben). The PAK2 shRNA lentiviral plasmid was co-transfected with the packaging constructs pMDLg/pRRE, pRSV-Rev and pCMV-VSV-G by Lipofectamine 2000 (Invitrogen) into human HEK293T cells cultured in 10% FBS DMEM (GIBCO). The lentiviral particles were freshly harvested and transduced into MCF7/IGF1R cells [14] . The stable shRNAmediated PAK2 knockdown MCF7/IGF1R cell lines were selected with puromycin and named MCF7/IGF1R shPAK2_1 and shPAK2_2, respectively. The shRNA control (shCtrl) pLKO.1-puro plasmid (SHC002, Sigma) targeting no known mammalian DNA was used to establish control cell line MCF7/IGF1R shCtrl.
pcDNA-PAK2 AMAXA transfection
The pcDNA3.1(+) vector containing hygromycin resistance gene (pcDNA-hygro) and pcDNA-hygro-PAK2 containing human PAK2 cDNA (pcDNA-PAK2) were kindly provided by Dr. Claude Backendorf (Leiden University, The Netherlands). Transient transfection of the pcDNA-hygro or pcDNA-PAK2 into MCF7/IGF1R shPAK2 cell lines was carried out by use of AMAXA Nucleofector® Kit V (LonzaBio) under program E-014.
Quantitative SILAC-based phospho-proteomics of MCF7/IGF1R cells under IGF-1 stimulation
To elucidate the signaling networks assembled by IGF-1R directly after receptor activation in MCF7/IGF1R cells in more detail, we initiated a global phospho-proteomic analysis using stable-isotope labeling by amino acids in cell culture (SILAC) [56, 57] . Briefly, SILAC labeling was performed in parallel, as schemed (Fig. 5a) . [58] and peptide fractionation by strong cation exchange chromatography, followed by titanium-dioxide phosphorpeptide enrichment [59] . MS analysis was performed on the LTQ-Orbitrap Velos mass spectrometer with high-energy collisional dissociation fragmentation. Raw MS files were analyzed with MaxQuant.
Flow cytometry cell cycle assay
Cells (200,000/well) were seeded in 12-w cell plate overnight, starved for 2 days in 5% CDFBS medium, and then treated under drug conditions as indicated. The time after 2-day starvation and before drug treatment was considered to be Day 0. Cells were then harvested after 4-day treatment, fixed with cold 100% ethanol and labeled in staining solution containing 10μM propidium iodide (PI) and 50 ng/ ml RNase A (BD Cycletest TM Plus DNA Reagent Kit, BD Biosciences). Cells were analyzed by use of FACSCanto II flow cytometer (BD Biosciences). The percentage of cells in G0/G1, S and G2/M phases were determined from 10,000 ungated cells (cell events) using the FACSDiva Software v6.1.2 (BD Biosciences).
Annexin V apoptosis assay
To detect apoptosis, a live cell imaging of Annexin VAlexa633 labeling was performed in real time, as described previously [60] . Briefly, 10,000 cells/well were seeded in 96-well plate. Following 2-day starvation in 5% CDFBS medium, cells were treated as indicated and labeled with Annexin V-Alexa633 (250 ng/ml) that conjugates to phosphatidyl serine on the membranes of apoptotic cells. At the time points of day 0, 1, 2, 3, and 4, the Annexin V in-taken cells were captured under Cy5 channel and the whole cell population was imaged under transmitted light by use of BD pathway 855 imager (Becton Dickinson). Simultaneously, the nuclei of live cells were stained with DNA dye Hoechst 33342 (200 ng/ml) and imaged for cell density. The number of Annexin V positive cells and the total cell number in each well were quantified using Image Pro (Media Cybernetics, Bethesda, MD, USA). Annexin V apoptosis fraction was calculated by normalization of Annexin V positive cells to the total cell number.
Experimental statistical analysis
Each average value was derived from triplicate experimental samples. Statistical analysis of all experimental data was performed using a two-sided Student's t-test. Data were expressed as mean ± SD. Significance was set at P < 0.05.
Ethics statement
The retrospective studies were approved by the medical ethics committee of the Erasmus MC Rotterdam, the Netherlands (MEC 02.953) and included coded fresh frozen and/or formalin-fixed, paraffin-embedded primary breast tumor tissue specimens from patients with primary operable breast cancer between 1985 and 2000. It was carried out according the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands (http://www.fmwv. nl) and reported, wherever possible, following the REMARK guidelines [61] .
Patients gene expression data
Patients with primary operable breast cancer were included in study who subsequently developed MBC treated with first-line tamoxifen and for which detailed clinical followup was available. For the gene expression microarray analyses, a cohort of 101 patients was investigated. This cohort has already been described by us previously [24] . The tissue microarray analyses used a cohort of 250 patients that has been described by us [38] , but includes now 41 additional patients. Briefly, for 291 of the 378 available patients ERpositive tumor core biopsies of the breast TMA were selected for further analyses. Of these 291 patients, 128 (44%) patients underwent breast conserving surgery and 163 modified mastectomy (56%). Median follow-up time after start therapy for patients alive was 42 months (range 6-188 months). All patients received first-line tamoxifen, and of these were 174 patients (60%) hormone-naïve and 117 patients (40%) received adjuvant chemotherapy. Response to therapy was observed in 181 patients (62%) whereas 110 patients (38%) did not have clinical benefit. The patients with response included 7 patients (4%) with complete response, 50 patients (28%) with partial response and 124 patients (68%) with stable disease for more than six months.
Patient tissue microarrays and immunohistological evaluation
Tissue microarrays of all formalin-fixed, paraffin-embedded primary breast tumor specimens were prepared and immunohistochemically stained according to the procedures described previously [38] . The staining was performed with the primary mouse monoclonal antibody against PAK2 and incubated for 1 hour (1:50 dilution) after 40 min antigen retrieval at pH9.0. Subsequently, TMA slides were incubated with a secondary antibody and staining was visualized using diaminobenzidine. PAK2 protein staining was scored for quantity and intensity by two independent observers, using Slidepath software (Leica Biosystems, Dublin). For the web-based scoring, stained TMAs were digitalized by a Hamamatsu Nanozoomer 2.0 HT (Hamamatsu photonics, Hamamatsu, Japan at magnification × 20 (0.45 μm/pixel resolution). Staining was grouped according to standardized categories for the estimated percentage of PAK2 positive cells (0%, 1-4% positive cells, 5-10%, 11-20%, 21-30%, 31-40%, 41-50%, 51-99%, 100%) and staining intensity as exemplified in Fig. 8a (negative, weak, moderate, strong) . More information for patients, ethics statement, data analysis and statistical methods, see supplemental information.
Patient data analysis and statistics
Statistical analyses were performed with STATA statistical package, release 13.0 (STATA Corp., College Station, TX, USA). Pearson's chi-squared, Mann-Whitney U tests, and Fisher's exact test were used to investigate the association between PAK2 protein expression and clinicopathological factors. HR with 95% CI was computed by the Cox proportional hazard model to assess the relationship between PAK2 protein expression and PFS after first-line therapy with tamoxifen. The endpoint PFS was defined as the time elapsed between start of tamoxifen therapy and the first detection of disease progression or death, whatever came first during treatment [38] . A multivariate analysis was performed to determine whether PAK2 expression had predictive value and was independent when added to base model of clinicopathological factors. Survival curves were generated by the Kaplan-Meier method. The log-rank test and log-rank test for trends were used to test for differences between survival curves. The P-values were two sided and P < 0.05 was considered as statistically significant.
